Please assess the completion status of the following clinical trial:

Trial Title: A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has a documented clinical diagnosis of asthma defined by the ATS for at least 6 months prior to Visit 2~* Have a morning pre-bronchodilator clinic FEV1 measured at least 6 hours after the last dose of inhaled SABA and at least 48 hours after last dose of inhaled LABA of 60% to 100% of predicted normal~* Demonstrated reversibility of clinic FEV1 of ≥12% from pre -albuterol/salbutamol level within 15 to 30 minutes after administration of a standard dose of albuterol/salbutamol.~Exclusion Criteria:~* Have been hospitalized at least once or required emergency treatment more than once for an asthma-related condition during the 6 months prior to Visit 1~* Have required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 6 weeks prior to Visit 1

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Symbicort pMDI 80/2.25 µg (Type: ACTIVE_COMPARATOR): Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
- Symbicort pMDI 80/4.5µg (Type: ACTIVE_COMPARATOR): Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
- Budesonide pMDI (Type: ACTIVE_COMPARATOR): Budesonide pMDI 80µg, 2 acuations twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).